baber/WOPTO huggingface dataset:
Patent NZ-532162-A (NZ)
Title: Acidic drinks containing tofu puree
Inventor: SOTOYAMA KAZUYOSHI
IPC: A23L25/10
Filed: 2002-07-09
Abstract: Disclosed is an acidic drink containing a tofu puree, having improved texture and flavour, and being free from the separation of components during storage, the acidic drink characterized by comprising, as a raw material, a tofu puree having the following physicochemical properties a) to d) a) having a viscosity of 20 to 3,000 mPa.s; b) having a dynamic storage modulus of 0.2 to 600 Pa; c) having a dynamic loss modulus of 0.2 to 250 Pa; and d) containing particles having an average particle diameter of 2 to 15 pin, and a 90% particle diameter of 35 pin or less.
Patent NZ-532584-A (NZ)
Title: Stowable tarpaulin for trucks
Inventor: BERGERO STEPHEN
IPC: B60P7/04
Filed: 2004-04-29
Abstract: Apparatus for draping a flexible cover over the bin of a vehicle is disclosed, which comprises rollup means for unrolling and rolling up a flexible cover and means for elevating the rollup means from a storage position to a feed out position, wherein the cover has a pair of side flaps and flap ties which extend at least partly over the sides of the bin and are rolled up and released by the rollup means, and wherein the rollup and release means have a guide aligned with each longitudinal edge of the tarpaulin capable of folding the side flaps and flap ties to lie coplanar with the tarpaulin during rollup.
Patent NZ-539123-A (NZ)
Title: Single-sided crash cushion system
Inventor: REID JOHN D
IPC: F16F7/12
Filed: 2003-09-30
Abstract: A single sided crash attenuation cushion system (100) having an impact head (104) and a three stage energy absorption mechanism. Each stage of the energy absorption mechanism provides an increasing level of kinetic energy dissipation as the cushion system collapses. The third stage of the absorption mechanism includes an additional deformable compressible tube (601) between the fixed-object hazard (600) and the thin walled tubes (650).
Patent NZ-546347-A (NZ)
Title: Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
Inventor: BLATT LAWRENCE M
IPC: A61K/
Filed: 2004-10-13
Abstract: Disclosed are compounds of formulae I, VIII and IX, wherein the substituents are as defined in the specification. The compounds are useful in the treatment of hepatitis C virus infections and liver fibrosis.
Patent NZ-547016-A (NZ)
Title: Method and device for dispensing from liquid concentrates beverages having multi-layer visual appearance
Inventor: SHER ALEXANDER
IPC: A47J31/40
Filed: 2004-09-30
Abstract: The disclosure relates to a method for dispensing a beverage with the visual appearance of multi-layers obtained from dilution of concentrates in proper dilution ratios. A first liquid layer (10) is first delivered with a controlled density. A second liquid layer (12) is diluted to a density that is lower than the density of the first liquid layer so that the first and second layers form a stable layered arrangement with the second liquid layer of lower density remaining spatially above the first liquid layer to provide a visually distinct layer as compared to the first liquid layer in the container. The invention also relates to a dispensing device and to a machine readable program enabling the device to deliver the multi-layer appearance beverage according to the method of the invention.
Patent NZ-552061-A (NZ)
Title: CETP Inhibitors
Inventor: ALI AMJAD
IPC: A61K31/4015
Filed: 2005-07-01
Abstract: Disclosed is a compound having Formula Ie, where the substituents are described in the specification, which inhibit cholesterol ester transfer protein (CETP). Also disclosed is the use of the compound for raising HDL-C in a patient and treatment of atherosclerosis
Patent NZ-554214-A (NZ)
Title: Rnai modulation of apob and uses thereof
Inventor: SOUTSCHEK JUERGEN
IPC: A61K31/70
Filed: 2005-09-26
Abstract: Provided is an iRNA agent comprising a sense strand having at least 17 contiguous nucleotides of sense strand sequence of a specified sequence and an antisense strand having at least 15 contiguous nucleotides of the antisense sequence. Further provided are modified forms of the iRNA agents and methods of making them as well as corresponding pharmaceutical compositions.
Patent NZ-567802-A (NZ)
Title: Use of a L-pyroglutamate and D-pyroglutamate mixture in a ratio between 80:20 to 97:3 for improving growth and/or yield of plants
Inventor: UNKEFER PAT J
IPC: A01N25/02
Filed: 2006-11-06
Abstract: Discloses a composition comprising a mixture of L- and D pyroglutamate stereoisomers in a ratio of L to D of from about 80:20 to about 97:3; and a carrier medium for application to a plant. Further disclosed is a method of increasing the agronomic performance of a plant and a method of treating seeds comprising treating said plant or seed with said composition.
Patent NZ-569372-A (NZ)
Title: A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
Inventor: BURMAN ANAND C
IPC: C08F220/00
Filed: 2006-12-26
Abstract: Disclosed is a polymer comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIP AM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and containing respective toxic monomeric contaminants in amounts less than 0.001 percent. Also disclosed is a process for preparation of said polymer comprising the steps of i) Dissolving appropriate quantities of the three monomers, NIPAM, VP and MPEG in water; ii) Adding in succession to the solution of step i), appropriate quantities of a crosslinking agent and an activator; iii) Bubbling an inert gas into the solution of step ii) for a period of between 30 to 60 minutes; iv) Adding an appropriate quantity of an activator and a polymerization initiator to the solution of step iv); v) Polymerization of the solution of step iv), at a temperature of between 25 degrees C to 45 degrees C, under an atmosphere of an inert gas for 3 to 6 hours; vi) Subjecting the solution of step v) to filtration through pre-sterilized filters and collecting the filtrate; vii) Subjecting the filtrate of step vi) to diafiltration and collecting the filtrate.
Patent NZ-570186-A (NZ)
Title: Polypeptides with laccase activity
Inventor: STROMPL CARSTEN
IPC: C12N9/02
Filed: 2007-02-23
Abstract: Provided is a polypeptide encoding a laccase, which can be used for lignin processing and as an animal food additive for pasture fed animals as well as for the preparation of beverages, including wine.
Patent NZ-577413-A (NZ)
Title: Pre-formed cheese layer for pizza with channels, typically cylindrical, for strenght during handling, with even layer when cooked
Inventor: YOUNG IAN
IPC: A23L5/30
Filed: 2007-11-29
Abstract: The pre-formed cheese layer has a thickness enabling handling during pizza preparation without breaking. Channels are provided so that the layer can cover the pizza base with the layer melting during cooking thereby filling in the channels and providing an even cooked layer on the pizza.
Patent NZ-578451-A (NZ)
Title: Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.
Inventor: FERRARI MASSIMO
IPC: A61K31/381
Filed: 2009-07-16
Abstract: Disclosed is an inclusion complex of raloxifene hydrochloride and b-cyclodextrin (wherein the inclusion complex has the following peaks at diffraction degrees (2-theta) in the X-ray powder diffraction spectrum ±0.2: 10.6, 12.4, 14.4, 15.3, 19.0 and 19.5). Also disclosed is a process for obtaining the inclusion complex of raloxifene hydrochloride with b-cyclodextrin as defined above which comprises the following steps: A) dissolving raloxifene hydrochloride in an aqueous solution; B) heating the mass to a temperature ranging from 50 to 80°C; C) adding b-cyclodextrin; D) separating the raloxifene hydrochloride-b-cyclodextrin complex by precipitation and filtration. Further disclosed is the use of an inclusion complex as defined above for manufacturing a medicament for the treatment of osteoporosis or postmenopausal osteoporosis.
Patent NZ-583404-A (NZ)
Title: Fluid blending system to blend fluid from multiple storage containers and return the mixed fluid to at least one container
Inventor: POLICKI PETER
IPC: A47J31/00
Filed: 2008-07-29
Abstract: The plurality of source fluid storing (1, 2 3) is for storing the respective component fluids. The blending means (210) receive the component fluids by fluid communication means (111, 121, 131) from the plurality of source fluid storing means to form a blended fluid. The distribution means (140) convey and deliver the blended fluid to one or more of the plurality of source fluid storing means.
Patent NZ-583562-A (NZ)
Title: Site-specific serine recombinases from Streptococcus pyogenes phage SF370.1 and Bacillus subtilis pahge recombinase SPbetac2and methods of their use
Inventor: PADIDAM MALLA
IPC: C12N15/85
Filed: 2005-02-08
Abstract: A method for obtaining site-specific recombination in an isolated eukaryotic cell comprising: - Providing an isolated eukaryotic cell that comprises a first recombination site and a second recombination site; - Contacting the first and second recombination site with a prokaryotic recombinase polypeptide resulting in recombination between the two sites; -The first recombination site is either a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB) and the second recombination is either attP or attB, provided that when the first recombination site is attP the second recombination site is attB or vice versa; - The recombinase is a Streptococcus pyogenes phage recombinase or a Bacillus subtilis phage recombinase, in particular, the recombinases are SF370.1 or SPbetac2 recombinase. The method also encompasses the use of pseudo attP and attB recombination sites as well as a third and fourth, and a fifth and sixth recombination site.
Patent NZ-585628-A (NZ)
Title: Humanized anti-beta 7 (integrin) antagonists and uses therefor
Inventor: DENNIS MARK S
IPC: A61K39/395
Filed: 2005-09-02
Abstract: Discloses a humanized antibody directed towards epitopes of the human beta-7 integrin protein subunit. The application discloses the amino acid sequences of the immunoglobulin light and heavy chain variable regions. Further disclosed is the use of the antibody in the manufacture of a medicament for treating beta-7 integrin-mediated disorders.
Patent NZ-592483-A (NZ)
Title: Compositions and methods for treating hoof diseases
Inventor: DEMARCO ROBERT J
IPC: A61K31/045
Filed: 2009-11-25
Abstract: ABSTRACT - 592483 The disclosure relates to a method for treating an animal that has or is at risk for one or more infectious diseases of the hoof, wherein said infectious disease comprises an open lesion on the lower leg and/or hoof area of said animal, said method comprising: administering to a lower leg and/or hoof area of said animal a composition that is substantially free of copper and zinc, said composition comprising at least one aldehyde selected from glutaraldehyde and glyoxal in an amount of about 5% to about 30% by weight, and wherein the composition comprises an effective amount of said aldehyde such that if an animal has the one or more infectious diseases, the composition causes formation of a scab over the lesion; wherein said composition may further comprise about 5% to 20% by weight of at least one quaternary ammonium compound; about 0.03% to 3% by weight of at least one poly(alkylene glycol) alkyl ether; about 0.03% to 3% by weight of at least one gelling agent; about 0.03% to 3% by weight of at least one antimicrobial essential oil or active thereof; and about 0.03% to 5% by weight of at least one surfactant.
Patent NZ-595224-A (NZ)
Title: Specific binding proteins and uses thereof
Inventor: OLD LLOYD J
IPC: A61K39/395
Filed: 2010-02-17
Abstract: 595224 Disclosed is an antibody with a heavy chain comprising of SDFAWN, YISYSGNTRYQPSLKS and VTAGRGFPY with a light chain consisting of SEQ ID NO: HSSQDINSNIG, HGTNLDD and VQYAQFPWT. Said antibody is capable of binding to amplified epidermal growth factor (EGFR) and to the de2-7 EGFR truncation, wherein the antibody does not bind to the de2-7 junctional peptide of SEQ ID NO: 14 and binds to an epitope within SEQ ID NO: 14 of human wild-type EGFR. Also discloses a pharmaceutical composition and use of the antibody for the treatment and prevention of cancer, glioblastomas, medulloblastomas, meningiomas, neoplastic astrocytomas and neoplastic arteriovenus malformations.
Patent NZ-596687-A (NZ)
Title: Vibration detection system for wind trubines with multiple vibration sensors
Inventor: SU LIYING
IPC: F03D11/00
Filed: 2011-11-25
Abstract: Disclosed is a vibration detecting device for a wind turbine generator. The device is comprised of a plurality of vibration sensors (100), at least one vibration switch (200), a vibration estimating module (300) and a control module (400). The vibration sensors (100) are arranged on a plurality of components of a wind turbine generator system to acquire vibration states of the components and generate vibration signals. The plurality of vibration sensors (100) includes a plurality of low-frequency vibration sensors and a plurality of high-frequency vibration sensors. The low frequency vibration sensors are arranged on a blade, a main shaft and a tower of the wind turbine generator system. The high-frequency vibration sensors are arranged on a gearbox and a generator of the wind turbine generator system. The vibration switch (200) is arranged on a nacelle of the wind turbine generator system to detect a vibration signal of the nacelle and send a fault signal generated by the vibration switch (200) to the control module (400) if the detected vibration signal of the nacelle is larger than a turn-on threshold. The vibration estimating module (300) is connected with the plurality of vibration sensors (100) and used for processing the vibration signals generated by the plurality of vibration sensors (100) according to preset weighted values and a weighted formula. This enables the acquisition of vibration state data of the wind turbine generator system. The vibration state data of the wind turbine generator system is compared with a preset fault value and a fault signal generated by the vibration estimating module (300) is sent to the control module (400) if the vibration state data is not less than the fault value. The weighted formula used by the vibration estimation module (300) is Z=(a1z1 + a2z2 + ... + anzn), wherein a1, a2, ... an represent the weighted values, and z1, z2, zn represent the generated vibration signals. The control module (400) is connected with the vibration switch (200) and the vibration estimating module (300) and used for shutting down the wind turbine generator system after receiving the fault signal generated by the vibration switch (200) or the fault signal generated by the vibration estimating module (300).
Patent NZ-601123-A (NZ)
Title: Panelized structural system for building construction
Inventor: VANKER JOHN LOUIS
IPC: E04B1/18
Filed: 2010-12-09
Abstract: A building section comprises a first structural column having a top connector and a bottom connector, a second structural column having a top connector and a bottom connector. The top connector of the first structural column is connected directly to the bottom connector of the second structural column so that the first and second structural columns are directly connected and align vertically. A first structural truss panel is attached to the first structural column, and a second structural truss panel attached to the second structural column such that the first and second structural truss panels transfer vertical live and dead loads and lateral loads on the first and second structural truss panels laterally to the first and second structural columns and then vertically through the first and second structural columns. A clearance exists between the first and second truss panels and between the first and second truss panels and any floor connected to the first and second truss panels such that load is not transferred between the first and second truss panels.
Patent NZ-603096-A (NZ)
Title: Crate
Inventor: ORGELDINGER WOLFGANG
IPC: B65D6/00
Filed: 2011-03-28
Abstract: 603096 Disclosed is A crate (100) comprising a bottom (110) and two respective pairwise opposing side walls (120) and two respective pairwise opposing end walls (130). The bottom of the crate is arch-shaped, curving towards the interior of the crate. The bottom comprises a plurality of rectangular vent openings (see 210 & 220, figure 2), arranged along a central longitudinal axis parallel to the side walls. The crate is able to accommodate protruding product from a crate stacked underneath, while also providing ventilation for that protruding product.
Patent NZ-604214-A (NZ)
Title: Headgear assembly for a respiratory mask assembly
Inventor: AMARASINGHE AMAL SHIRLEY
IPC: A62B18/08
Filed: 2003-09-05
Abstract: A headgear assembly is disclosed for maintaining a frame and cushion of a respiratory mask assembly in position on a patient user’s face. The assembly is constructed from a soft, flexible material and has two side portions and a rear portion between the side portions. Each side portion includes an upper side strap (22) to be located above the ear and eye of a user, and a lower side strap (24) to be located below the ear and eye of a user. The upper (22) and lower (24) side straps are connectable to a frame. The rear portion has a stiffening layer (46) which maintains the position of respective upper (22) and lower (24) side straps of the side portions spaced from the user’s ears.
Patent NZ-608196-A (NZ)
Title: Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
Inventor: XUEDONG DAI
IPC: A61K31/16
Filed: 2009-08-19
Abstract: Disclosed are prodrugs of methyl hydrogen fumarate (monomethyl fumarate) according to formula (I), and methods for their preparation. Specific examples of compounds of formula (I) include: (2E)-3-[(2-morpholin-4-yl-2-oxoethyl)oxycarbonyI]prop-2-enoic acid; (2E)-3-{ [(N,N-diethylcarbamoyl)methyI]oxycarbonyl} prop-2-enoic acid; (2E)-3-({ [N-benzylcarbamoyI]methyl} oxycarbonyl) prop-2-enoic acid. Compounds of formula (I) are useful for treating psoriasis, asthma, chronic obstructive pulmonary disease, cardiac insufficiency, left ventricular insufficiency, myocardial infarction, angina pectoris, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, retinopathia pigmentosa, mitochondrial encephalomyopathy, transplantation rejection, multiple sclerosis,ischemia, reperfusion injury, AGE induced genome damage, inflammatory bowel disease, Crohn’s disease, or ulcerative colitis.
Patent NZ-611859-A (NZ)
Title: Antibody purification
Inventor: WAN MIN W
IPC: C07K1/36
Filed: 2007-04-04
Abstract: Disclosed is a liquid composition comprising an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, wherein the composition has no detectable cathepsin L activity as determined by a cathepsin L kinetic assay; wherein the anti-TNFα antibody or antigen-binding portion comprises: 1. A light chain variable region comprising: - a light chain CDR3 comprising the amino acid sequence of QRYNRAPYX or an amino acid sequence differing from QRYNRAPYX by a single alanine substitution at position 1, 4, 5, 7 or 8; - a light chain CDR2 comprising the amino acid sequence of AASTLQS; and - a light chain CDR1 comprising the amino acid sequence of RASQGIRNYLA; and 2. A heavy chain variable region comprising: - a heavy chain CDR3 comprising the amino acid sequence of VSYLSTASSLDX or an amino acid sequence differing from VSYLSTASSLDX by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11; - a heavy chain CDR2 comprising the amino acid sequence of AITWNSGHIDYADSVEG; and - a heavy chain CDR1 comprising the amino acid sequence of DYAMH.
Patent NZ-612089-A (NZ)
Title: Deblocking filtering
Inventor: NORKIN ANDREY
IPC: H04N19/174
Filed: 2011-10-06
Abstract: Disclosed is a method reduces blocking artifacts at a block boundary between a block and a neighboring block in a video frame is disclosed. The method comprises calculating an offset based on pixel values of pixels (11, 13) in a line (12) of pixels (11, 13, 15, 17) in the block (10) and based on pixel values of pixels (21, 23) in a corresponding line (22) of pixels (21, 23, 25, 27) in the neighboring block (20). The offset is added to the pixel value of the pixel (11) closest to the block boundary (1) in the line (12) of pixels (11, 13, 15, 17) and is subtracted from the pixel value of the pixel (21) closest to the block boundary (1) in the corresponding line (22) of pixels (21, 23, 25, 27). A system to perform this method is also disclosed.
Patent NZ-617025-A (NZ)
Title: (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
Inventor: HAUCK GERRIT
IPC: A61K31/277
Filed: 2010-09-14
Abstract: 617025 Disclosed herein is a solid pharmaceutical composition comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluoromethylphenyl)-amide (formula I, teriflunomide), wherein the pH of the composition is less than 2.2, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.
Patent NZ-621367-A (NZ)
Title: Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
Inventor: ALAVATTAM SREEDHARA
IPC: C07K16/32
Filed: 2012-10-11
Abstract: The disclosure relates to Use of Pertuzumab and Trastuzumab in the manufacture of a medicament for treating early-stage HER2-positive breast cancer in a patient, wherein the medicament is for administration with carboplatin-based chemotherapy comprising Docetaxel and Carboplatin. Also disclosed are articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor and uses thereof, methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; treating early-stage HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. Also described is an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the disclosure relates to an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.
Patent NZ-714415-A (NZ)
Title: Substituted nucleosides, nucleotides and analogs thereof
Inventor: DYATKINA NATALIA
IPC: C07H19/20
Filed: 2014-06-24
Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
Patent NZ-718739-A (NZ)
Title: Compounds for the control of endoparasites
Inventor: GAUVRY NOËLLE
IPC: C07D401/06
Filed: 2014-11-14
Abstract: The invention relates to compounds of the general formula (I) wherein the variable have the meanings as indicated in the claims, or a physiologically acceptable salt thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling endoparasites in warm-blooded animals.